Novo Nordisk convinced a group of FDA advisers that its liraglutide, already a blockbuster diabetes treatment, can effectively combat obesity, clearing the way for a second indication that could add $1 billion to its annual sales.

…read more

Source: FDA panel backs Novo’s weight-loss plan with new liraglutide nod


0 No comments